股市必读：英科医疗（300677）5月30日主力资金净流入2832.99万元

Core Viewpoint - Inke Medical (300677) has announced a 2025 restricted stock incentive plan aimed at attracting and retaining talent, aligning the interests of shareholders, the company, and its core team [3][4][7]. Group 1: Stock Performance and Trading Information - As of May 30, 2025, Inke Medical's stock closed at 23.71 yuan, up 4.45%, with a turnover rate of 6.64%, trading volume of 311,300 shares, and a transaction value of 748 million yuan [1]. - On the same day, the capital flow showed a net inflow of 28.33 million yuan from main funds, while retail and speculative funds experienced net outflows of 14.44 million yuan and 13.88 million yuan, respectively [2]. Group 2: Board and Supervisory Meetings - The fourth board of directors held its fifth meeting on May 29, 2025, where all seven directors attended and approved several resolutions, including the 2025 restricted stock incentive plan and the authorization for the board to handle related matters [3]. - The fourth supervisory board also convened on the same day, with all three supervisors present, and approved the same resolutions regarding the incentive plan, confirming its compliance with laws and regulations [4]. Group 3: Details of the Incentive Plan - The 2025 restricted stock incentive plan proposes to grant a total of 13.59 million shares, accounting for 2.10% of the company's total equity, with an initial grant of 13.22 million shares and a reserve of 370,000 shares [4][7]. - The grant price is set at 11.40 yuan per share, which is not less than 50% of the average trading price over the previous 20 trading days [4][7]. - The plan targets 1,102 individuals, including senior management and core personnel, and will not provide any financial assistance to the incentive recipients [5][7]. Group 4: Performance Assessment and Conditions - The incentive plan includes performance assessment targets for the company covering revenue and net profit from 2026 to 2029, with individual performance assessments affecting the actual release of shares [7]. - The plan has a maximum validity period of 69 months, with lock-up periods of 21, 33, 45, and 57 months, each releasing 25% of the shares [7].